In-practice Evaluation of Atacand 16mg Antihypertensive Effect

AstraZeneca400 enrolled

Overview

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Essential Hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least \<140/90 mgHg and the doctor has decided * Signed and dated Patient Informed Consent (ICF) Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients of Atacand.

Locations (4)

Research site

Daugavpils, Latvia

Research site

Jelgava, Latvia

Research site

Liepāja, Latvia

Research Site

Riga, Latvia

Outcomes

Primary Outcomes

Decrease in blood pressure

Time frame: once after 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.